Loading organizations...
Glen Clova Scientific is a biotechnology company based in Dundee, Scotland, that develops active biologic drugs using a proprietary Virus-Like Particle technology platform to treat chronic inflammatory, autoimmune, and immuno-dermatology conditions. Founded in 2022 as a spin-out from the University of Dundee by Doctor John Foerster, the enterprise focuses on the medical needs of aging populations while exploring applications in companion animal health and diagnostics. The firm recently established new laboratories to advance the preclinical development of its lead assets. The company has raised 3,900,000 pounds in venture capital and grant funding, including an initial seed round of 2,500,000 pounds in April 2024 and a subsequent investment of 1,400,000 pounds in the first quarter of 2025. This financial backing was secured from a syndicate of investors that includes DSW Ventures, Norcliffe Capital, TriCapital Angels, and Scottish Enterprise.
Glen Clova Scientific has raised $5.0M across 1 funding round.
Glen Clova Scientific has raised $5.0M in total across 1 funding round.
Glen Clova Scientific has raised $5.0M across 1 funding round. Most recently, it raised $5.0M Seed in April 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 25, 2024 | $5M Seed | Patricia Reynolds | Doug Quinn, Scottish Enterprise, Tricapital | Announced |
Glen Clova Scientific has raised $5.0M in total across 1 funding round.
Glen Clova Scientific's investors include Patricia Reynolds, Doug Quinn, Scottish Enterprise, TRICAPITAL.
